ArticleMolecular neurobiology2017
Curcumin Ameliorates Memory Decline via Inhibiting BACE1 Expression and β-Amyloid Pathology in 5×FAD Transgenic Mice.
Article in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis.The journal of prevention of Alzheimer's disease · 2025Pooled it
- Curcumin and Dementia: A Systematic Review of Its Effects on Oxidative Stress and Cognitive Outcomes in Animal Models.International journal of molecular sciences · 2025Pooled it
- Therapeutic potential of curcumin on the cognitive decline in animal models of Alzheimer's disease: a systematic review and meta-analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer's Disease: A Systematic Review.Current neuropharmacology · 2019Pooled it
- When copper turns killer: Decoding copper dyshomeostasis and cuproptosis in neurodegenerative pathogenesis and precision metal interventions.Neural regeneration research · 2026Article
- ACSS2 maintains oligodendrocyte progenitor cell pool and is required for myelination during development and aging.Nature aging · 2026Article
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
- Improved cognition and memory via PLGA nanoparticle-mediated delivery of curcumin and piperine in an in vivo Alzheimer's disease model.Drug delivery and translational research · 2025Article
- Engineered nanoplatforms for brain-targeted co-delivery of phytochemicals in Alzheimer's disease: Rational design, blood-brain barrier penetration, and multi-target therapeutic synergy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Bone marrow B lymphopoiesis accelerates early cerebral amyloid pathology.Signal transduction and targeted therapy · 2025Article
- Mechanisms Linking Obesity, Insulin Resistance, and Alzheimer's Disease: Effects of Polyphenols and Omega-3 Polyunsaturated Fatty Acids.Nutrients · 2025Review
- Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.Pharmaceutics · 2025Review
- Regulation mechanism of curcumin mediated inflammatory pathway and its clinical application: a review.Frontiers in pharmacology · 2025Review
- Neuroprotective synergy of curcumin andFrontiers in pharmacology · 2025Article
- Polymers for the treatment of Alzheimer's disease.Frontiers in pharmacology · 2025Review
- Mechanism and Clinical Application Prospects of Mitochondrial DNA Single Nucleotide Polymorphism in Neurodegenerative Diseases.Neurochemical research · 2024Review
- Potential Protective Effects of Pungent Flavor Components in Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2024Review
- Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment.Antioxidants (Basel, Switzerland) · 2024Review
- Synergistic activity of nootropic herbs as potent therapeutics for Alzheimer's disease: A cheminformatics, pharmacokinetics, and system pharmacology approach.Journal of Alzheimer's disease reports · 2024Article
- Curcumin Mitigates Malathion-Induced Renal Injury: Suppression of Apoptosis and Modulation of NF-κβ/TNF-α and Nrf2, and HO-1 Signaling.Metabolites · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common dementia and the trigger of its pathological cascade is widely believed to be the overproduction and accumulation of β-amyloid protein (Aβ) in the affected brain. However, effective AD remedies are still anxiously awaited. Recent evidence suggests that curcumin may be a potential agent for AD treatment. In this study, we used 5×FAD transgenic mice as an AD model to investigate the effects of curcumin on AD. Our results showed that curcumin administration (150 or 300 mg/kg/day, intragastrically, for 60 days) dramatically reduced Aβ production by downregulating BACE1 expression, preventing synaptic degradation, and improving spatial learning and memory impairment of 5×FAD mice. These findings suggest that curcumin is a potential candidate for AD treatment.
Indexed as
Identifiers
26910813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.